Table 5.
Review of literature for prostective studies for SBRT for liver metastases.
| Author (year) | Design | Patients | Primary | Dose/fractionation | Platform | Toxicity (cases) | Local control | OS |
|---|---|---|---|---|---|---|---|---|
| Herfarth (2001)22 | Phase I-II | 35 | NR | 14−26 Gy/ 1 | Linac | No serious toxicity | 1-year LC 71% | 1-year OS 72% |
| 18-mo LC 67% | ||||||||
| Schefter (2005)31 | Phase I | 18 | Mixed | 36−60 Gy/ 3 | Linac | No patients experience | NR | NR |
| dose-limiting toxicity | ||||||||
| Hoyer (2006)32 | Phase II | 64 (44) | CRC | 45 Gy/ 3 | Linac | 1 liver failure | 1-year LC 95% | 1-year OS 67% |
| 2 severe late GI | 2-years LC 79% | 2-years OS 38% | ||||||
| Mendez Romero (2006)33 | Phase I-II | 25 (17) | Mixed | 30−37.5 Gy/ 3 | Linac | Grade 3 liver toxicity (2) | 2-years LC 86% | 2-years OS 62% |
| Lee (2009)34 | Phase I-II | 68 | Mixed | 27.7−60 Gy/ 6 | Linac | 10% acute Grade 3−4 | 1-year LC 71% | Median 17.6 months |
| Rusthoven (2009)35 | Phase I-II | 47 | Mixed | 36−60 Gy/ 3 | Linac | <2% Grade 3−4 late toxicity | 1-year LC 95% | Median 20.5 months |
| 2-years LC 92% | ||||||||
| Ambrosino (2009)36 | Prospective | 27 | Mixed | 25−60 Gy /3 | CK | No serious toxicity | Crude LC 74% | NR |
| Goodman (2010)37 | Phase I | 26 (19) | Mixed | 18−30 Gy / 1 | Linac/CK | Grade 2 late toxicity (4) | 1-year LF 23% | 1-year OS 61.8% |
| 2-years OS 49% | ||||||||
| Scorsetti (2013)38 | Phase II | 61 | Mixed | 75 Gy / 3 | Linac | Grade 3 late toxicity (1) | 1-year LC 94% | 1-year OS 84% |
NR: not reported; LC: local control; OS: overall survival; CRC: colorectal carcinoma; CK: Cyberknife System.